The growing importance of pharmacoeconomics: the case of age-related macular degeneration.
Smith
A F
AF
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D011157:Population Dynamics; D015995:Prevalence; D011817:Rabbits
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab